Narrow-moat Merck KGaA MRK delivered weak second-quarter results, and with these trends, management reduced its 2023 outlook. Mild tinkering with our near-term expectations does not materially affect ...

Narrow-moat Merck KGaA's fourth-quarter results reflected continued challenges in its life science and semiconductor end markets. The firm generated results within its target ranges for 2023, albeit a ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck's Life ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life ...

Merck, a leading science and technology company, has opened its new $176 million filtration manufacturing facility at Blarney Business Park, Co. Cork. This site is Merck’s first manufacturing facility ...

Basic science is regarded as the starting point for numerous industries as it is essential not only to discovering new drugs but also to advancing cutting-edge technologies such as semiconductors and ...

After posting revenue increases for six straight years, including double-digit growth in 2021 and 2022, Merck KGaA took a hard fall last year, with its global sales declining by 6% to 21 billion euros ...

The life sciences industry is primed for growth in 2024 as new life, if you will, is breathed into the industry. In New Jersey, one of the top markets nationwide for the sector, that story is playing ...

The low-profile developer behind a major King’s Cross life sciences scheme will push on and complete the project, even after global pharmaceutical giant Merck pulled out of the building. Merck said on ...

We are now working to make pimicotinib available to patients in China as quickly as possible, as we continue to progress applications with regulatory authorities in additional markets.” TGCT is a rare ...